CompletedPhase 2NCT02397928
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NovoCure Ltd.
- Principal Investigator
- Giovanni Luca Ceresoli, MDCliniche Humanitas Gavazzeni
- Intervention
- NovoTTF-100L device(device)
- Enrollment
- 82 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (13)
- Antwerp University Hospital, Thoracic Oncology, Antwerp, Belgium
- Goustave Roussy - Cancer Campus Grand Paris, Villejuif, France
- Universitätsklinikum Halle (Saale), Halle, Germany
- A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy
- Cliniche Humanitas Gavazzeni, Bergamo, Italy
- Ospedale Villa Scassi, Genoa, Italy
- Ospedaliera di Perugia, Perugia, Italy
- Ospedaliero Universitaria Pisana, Pisa, Italy
- Erasmus Mc, Rotterdam, Netherlands
- Medical University Gdansk, Gdansk, Poland
- Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland
- Klinika Nowotworów Pluca I Klatki Piersiowej, Warsaw, Poland
- Vall d' Hebron Institute of Oncology (VHIO) Hospital Vall d'Hebron, Barcelona, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02397928 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited